Overcoming fixed-dose combination challenges for ALS

OSD

Synchronizing Drug Release for Phase 3 Success: How Recipharm Helped NeuroSense Therapeutics Advance Prime C

When NeuroSense Therapeutics needed to develop an extended-release fixed-dose combination tablet, with matched release rates for two challenging APIs, they turned to Recipharm’s expert team.

Discover how our innovative formulation strategy enabled synchronized drug release, paving the way for successful progression to Phase 3 clinical trials.

Want the full story?
Fill in the form below to download the full case study and see how Recipharm delivers complex drug development solutions with precision and partnership.

First Name

Last Name

Company

Where are you based?

State/Province

I agree that Recipharm registers the above information and gives me information about services and products via email. Read more about our Privacy Policy

Hidden OSD

Hidden SFF

Hidden ADS

Hidden BU not set